Epoetin alfa is a recombinant form of erythropoietin, a glycoprotein hormone that stimulates red blood cell production in the bone marrow. It is primarily used in the treatment of anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy. Epoetin alfa is characterized by its ability to bind to erythropoietin receptors on erythroid progenitor cells, promoting their proliferation and differentiation into mature red blood cells. The substance is produced using recombinant DNA technology, which allows for the synthesis of a biologically active form of erythropoietin. Epoetin alfa is typically administered via subcutaneous or intravenous injection and is available in various formulations. Its pharmacokinetics include a relatively long half-life, allowing for less frequent dosing compared to other forms of erythropoietin. Common side effects may include hypertension, headache, and injection site reactions. As with any medication, its use should be monitored closely to avoid complications such as thromboembolic events.

Epoetin Alfa

113427-24-0: 1-165-Erythropoietin (human clone lambdaHEPOFL13 protein moiety), glycoform alpha, Epoade, Epogen, Eprex, Erypo, Erythropoeitin, Erythropoiesis stimulating factor, ESF, Espo, Procrit, R-HuEPO

Polypeptide, protein and glycoprotein hormones, their derivatives and structural analogues, nesoi

CAS 113427-24-0: Epoetin Alfa

Erythropoietin for Bioassays

Ref: 45-1248200

Erythropoietin

Ref: 45-1248218